MoCRA Is Here—Now What? Unpacking Litigation and Regulatory Risk for Cosmetics Brands Following MoCRA’s Enactment
Update Magazine | Spring 2023
An Overview of Food and Drug Law Practices, 2023 Update
Update Magazine | Spring 2023
Association of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion GalleryAssociation of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion
Association of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion
Update Magazine | Spring 2023
Establishing an FDA office in the Middle East/North Africa: An Abraham Accords Initiative
Update Magazine | Spring 2023
Direct-to-Patient Sample Distribution in the Time of COVID-19
Update Magazine | Winter 2022
Federal Funding of Medical Countermeasures: Opportunities, Risks, and Enforcement Trends
Update Magazine | Winter 2022
FDA Hosts Virtual Listening Session on Improving Regulation of Animal Foods with Certain Types of Claims
Update Magazine | Winter 2022
Adoption Patterns of the FDA Food Code Across U.S. States
Update Magazine | Winter 2022
Letter to the Editor
Update Magazine | Winter 2022
What’s in a Name? Updates on Plant-Based Product Labeling Regulations
Update Magazine | Fall 2022
